23-044-011
Quidel™ Lyra SARS-CoV-2 Molecular Assay
Manufacturer: Fischer Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Pack of 96 | 23-044-011-Pack-of-96 | In Stock | ₹ 3,24,272.40 |
23-044-011 - Pack of 96
In Stock
Quantity
1
Base Price: ₹ 3,24,272.40
GST (18%): ₹ 58,369.032
Total Price: ₹ 3,82,641.432
Certifications/Compliance
Emergency Use Authorization (EUA)
Control Sets
Included
Clia Complexity
High
DoA Calibrators
No
Sensitivity
PPA – 92/92 = 100% (95% CI: 95.99 to 100%)
For Use With (Application)
RT-PCR
Includes
Tests and controls
Quantity
96 Tests/Kit
Test Time
<75 min. after extraction
Content And Storage
2°C to 8°C
CE Marker
Yes
Detectable Analytes
SARS-CoV-2
Sample Type
Nasal, Nasopharyngeal, Oropharyngeal Swab
Type
Molecular Testing
For Use With (Equipment)
Emergency Use Authorization (EUA) for use on bioMerieux NucliSENS™ easyMAG™ system or EMAG system, followed by RT-PCR on one of six thermocyclers: Applied Biosystems™ 7500 Fast Dx, Applied Biosystems 7500 Standard, QuantStudioTM Real-Time PCR Instrument, Roche LightCycler™ 480, BioRad CFX96 Touch, or Qiagen Rotor-Gene Q
Packaging Type
Kit
Specificity
NPA – 92/92 = 100% (95% CI: 95.99 to 100%)
Form
Liquid
Related Products
Description
- RT-PCR One-step reagent setup Results in <75 minutes after extraction No freezer necessary Refrigration storage Flexible testing format Includes 12 x 8 master mix, rehydration solution and liquid process controls
SAFETY INFORMATION
- ShelfLife : 6 Months from DOM
Compare Similar Items
Show Difference
Certifications/Compliance: Emergency Use Authorization (EUA)
Control Sets: Included
Clia Complexity: High
DoA Calibrators: No
Sensitivity: PPA – 92/92 = 100% (95% CI: 95.99 to 100%)
For Use With (Application): RT-PCR
Includes: Tests and controls
Quantity: 96 Tests/Kit
Test Time: <75 min. after extraction
Content And Storage: 2°C to 8°C
CE Marker: Yes
Detectable Analytes: SARS-CoV-2
Sample Type: Nasal, Nasopharyngeal, Oropharyngeal Swab
Type: Molecular Testing
For Use With (Equipment): Emergency Use Authorization (EUA) for use on bioMerieux NucliSENS™ easyMAG™ system or EMAG system, followed by RT-PCR on one of six thermocyclers: Applied Biosystems™ 7500 Fast Dx, Applied Biosystems 7500 Standard, QuantStudioTM Real-Time PCR Instrument, Roche LightCycler™ 480, BioRad CFX96 Touch, or Qiagen Rotor-Gene Q
Packaging Type: Kit
Specificity: NPA – 92/92 = 100% (95% CI: 95.99 to 100%)
Form: Liquid
Certifications/Compliance:
Emergency Use Authorization (EUA)
Control Sets:
Included
Clia Complexity:
High
DoA Calibrators:
No
Sensitivity:
PPA – 92/92 = 100% (95% CI: 95.99 to 100%)
For Use With (Application):
RT-PCR
Includes:
Tests and controls
Quantity:
96 Tests/Kit
Test Time:
<75 min. after extraction
Content And Storage:
2°C to 8°C
CE Marker:
Yes
Detectable Analytes:
SARS-CoV-2
Sample Type:
Nasal, Nasopharyngeal, Oropharyngeal Swab
Type:
Molecular Testing
For Use With (Equipment):
Emergency Use Authorization (EUA) for use on bioMerieux NucliSENS™ easyMAG™ system or EMAG system, followed by RT-PCR on one of six thermocyclers: Applied Biosystems™ 7500 Fast Dx, Applied Biosystems 7500 Standard, QuantStudioTM Real-Time PCR Instrument, Roche LightCycler™ 480, BioRad CFX96 Touch, or Qiagen Rotor-Gene Q
Packaging Type:
Kit
Specificity:
NPA – 92/92 = 100% (95% CI: 95.99 to 100%)
Form:
Liquid
Certifications/Compliance: Emergency Use Authorization (EUA)
Control Sets: Included
Clia Complexity: High
DoA Calibrators: No
Sensitivity: PPA – 92/92 = 100% (95% CI: 95.99 to 100%)
For Use With (Application): RT-PCR
Includes: Tests and controls
Quantity: 96 Tests/Kit
Test Time: <75 min. after extraction
Content And Storage: 2°C to 8°C
CE Marker: Yes
Detectable Analytes: SARS-CoV-2
Sample Type: __
Type: Molecular Testing
For Use With (Equipment): Emergency Use Authorization (EUA) for use on bioMerieux NucliSENS™ easyMAG™ system or EMAG system, followed by RT-PCR on one of six thermocyclers: Applied Biosystems™ 7500 Fast Dx, Applied Biosystems 7500 Standard, QuantStudioTM Real-Time PCR Instrument, Roche LightCycler™ 480, BioRad CFX96 Touch, or Qiagen Rotor-Gene Q
Packaging Type: Kit
Specificity: NPA – 92/92 = 100% (95% CI: 95.99 to 100%)
Form: __
Certifications/Compliance:
Emergency Use Authorization (EUA)
Control Sets:
Included
Clia Complexity:
High
DoA Calibrators:
No
Sensitivity:
PPA – 92/92 = 100% (95% CI: 95.99 to 100%)
For Use With (Application):
RT-PCR
Includes:
Tests and controls
Quantity:
96 Tests/Kit
Test Time:
<75 min. after extraction
Content And Storage:
2°C to 8°C
CE Marker:
Yes
Detectable Analytes:
SARS-CoV-2
Sample Type:
__
Type:
Molecular Testing
For Use With (Equipment):
Emergency Use Authorization (EUA) for use on bioMerieux NucliSENS™ easyMAG™ system or EMAG system, followed by RT-PCR on one of six thermocyclers: Applied Biosystems™ 7500 Fast Dx, Applied Biosystems 7500 Standard, QuantStudioTM Real-Time PCR Instrument, Roche LightCycler™ 480, BioRad CFX96 Touch, or Qiagen Rotor-Gene Q
Packaging Type:
Kit
Specificity:
NPA – 92/92 = 100% (95% CI: 95.99 to 100%)
Form:
__
Certifications/Compliance: Emergency Use Authorization (EUA)
Control Sets: Included
Clia Complexity: High
DoA Calibrators: No
Sensitivity: PPA – 92/92 = 100% (95% CI: 95.99 to 100%)
For Use With (Application): RT-PCR
Includes: Tests and controls
Quantity: 96 Tests/Kit
Test Time: <75 min. after extraction
Content And Storage: 2°C to 8°C
CE Marker: Yes
Detectable Analytes: SARS-CoV-2
Sample Type: __
Type: Molecular Testing
For Use With (Equipment): Emergency Use Authorization (EUA) for use on bioMerieux NucliSENS™ easyMAG™ system or EMAG system, followed by RT-PCR on one of six thermocyclers: Applied Biosystems™ 7500 Fast Dx, Applied Biosystems 7500 Standard, QuantStudioTM Real-Time PCR Instrument, Roche LightCycler™ 480, BioRad CFX96 Touch, or Qiagen Rotor-Gene Q
Packaging Type: Kit
Specificity: NPA – 92/92 = 100% (95% CI: 95.99 to 100%)
Form: __
Certifications/Compliance:
Emergency Use Authorization (EUA)
Control Sets:
Included
Clia Complexity:
High
DoA Calibrators:
No
Sensitivity:
PPA – 92/92 = 100% (95% CI: 95.99 to 100%)
For Use With (Application):
RT-PCR
Includes:
Tests and controls
Quantity:
96 Tests/Kit
Test Time:
<75 min. after extraction
Content And Storage:
2°C to 8°C
CE Marker:
Yes
Detectable Analytes:
SARS-CoV-2
Sample Type:
__
Type:
Molecular Testing
For Use With (Equipment):
Emergency Use Authorization (EUA) for use on bioMerieux NucliSENS™ easyMAG™ system or EMAG system, followed by RT-PCR on one of six thermocyclers: Applied Biosystems™ 7500 Fast Dx, Applied Biosystems 7500 Standard, QuantStudioTM Real-Time PCR Instrument, Roche LightCycler™ 480, BioRad CFX96 Touch, or Qiagen Rotor-Gene Q
Packaging Type:
Kit
Specificity:
NPA – 92/92 = 100% (95% CI: 95.99 to 100%)
Form:
__
Certifications/Compliance: End-User Placement Agreement Required
Control Sets: Included and available for purchase
Clia Complexity: Waived (EUA)
DoA Calibrators: __
Sensitivity: Influenza A: NS - 90%, NPS - 97.1%Influenza B: NS - 89%, NPS - 90%SARS-CoV-2: 95.2%
For Use With (Application): Instrument Read - advanced immunofluorescence-based lateral flow
Includes: __
Quantity: 25
Test Time: 15 min.
Content And Storage: 15°C to 35°C
CE Marker: No
Detectable Analytes: Influenza A and B, COVID-19/2019-nCOV
Sample Type: Direct: Nasal Swab, Nasopharyngael Swab
Type: Rapid Test
For Use With (Equipment): __
Packaging Type: 12 Kits/Cs.
Specificity: Influenza A: NS - 95%, NPS - 94.6%Influenza B: NS - 96%, NPS - 97%SARS-CoV-2: 100%
Form: Liquid
Certifications/Compliance:
End-User Placement Agreement Required
Control Sets:
Included and available for purchase
Clia Complexity:
Waived (EUA)
DoA Calibrators:
__
Sensitivity:
Influenza A: NS - 90%, NPS - 97.1%Influenza B: NS - 89%, NPS - 90%SARS-CoV-2: 95.2%
For Use With (Application):
Instrument Read - advanced immunofluorescence-based lateral flow
Includes:
__
Quantity:
25
Test Time:
15 min.
Content And Storage:
15°C to 35°C
CE Marker:
No
Detectable Analytes:
Influenza A and B, COVID-19/2019-nCOV
Sample Type:
Direct: Nasal Swab, Nasopharyngael Swab
Type:
Rapid Test
For Use With (Equipment):
__
Packaging Type:
12 Kits/Cs.
Specificity:
Influenza A: NS - 95%, NPS - 94.6%Influenza B: NS - 96%, NPS - 97%SARS-CoV-2: 100%
Form:
Liquid